Li Di

14.8k total citations · 4 hit papers
184 papers, 8.6k citations indexed

About

Li Di is a scholar working on Pharmacology, Molecular Biology and Oncology. According to data from OpenAlex, Li Di has authored 184 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Pharmacology, 60 papers in Molecular Biology and 56 papers in Oncology. Recurrent topics in Li Di's work include Pharmacogenetics and Drug Metabolism (67 papers), Drug Transport and Resistance Mechanisms (52 papers) and Computational Drug Discovery Methods (31 papers). Li Di is often cited by papers focused on Pharmacogenetics and Drug Metabolism (67 papers), Drug Transport and Resistance Mechanisms (52 papers) and Computational Drug Discovery Methods (31 papers). Li Di collaborates with scholars based in United States, China and Canada. Li Di's co-authors include Edward H. Kerns, Dennis A. Smith, Tristan S. Maurer, Nicholas A. Meanwell, Michael J. Hageman, Jarkko Rautio, Paul V. Fish, Takashi Mano, Kevin Beaumont and Bo Feng and has published in prestigious journals such as Journal of the American Chemical Society, Neurology and Nature Reviews Drug Discovery.

In The Last Decade

Li Di

176 papers receiving 8.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery

2010 614 citations Li Di, Edward H. Kerns et al. profile →
The expanding role of prodrugs in contemporary drug design and development

2018 556 citations Li Di et al. profile →
Coexistence of passive and carrier-mediated processes in drug transport

2010 486 citations Li Di et al. profile →
Strategic Approaches to Optimizing Peptide ADME Properties

2014 479 citations Li Di The AAPS Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Li Di United States	48	3.5k	2.1k	1.7k	1.5k	1.2k	184	8.6k
Dennis A. Smith United Kingdom	40	2.5k 0.7×	1.8k 0.8×	2.8k 1.6×	1.4k 1.0×	703 0.6×	148	7.6k
Edward H. Kerns United States	38	2.5k 0.7×	1.1k 0.5×	814 0.5×	1.4k 0.9×	1.0k 0.9×	85	6.4k
Su Zeng China	49	4.2k 1.2×	1.8k 0.8×	1.6k 0.9×	338 0.2×	582 0.5×	392	9.7k
Peter W. Swaan United States	44	2.9k 0.8×	2.2k 1.0×	892 0.5×	686 0.5×	631 0.5×	129	6.9k
Kristina Luthman Sweden	39	2.4k 0.7×	1.3k 0.6×	504 0.3×	1.1k 0.7×	2.2k 1.9×	139	7.1k
Duxin Sun United States	61	8.3k 2.4×	3.3k 1.5×	766 0.5×	782 0.5×	1.4k 1.2×	281	14.9k
Gerd Folkers Switzerland	42	3.5k 1.0×	1.2k 0.6×	492 0.3×	1.5k 1.0×	1.1k 0.9×	192	7.6k
Amit S. Kalgutkar United States	51	3.0k 0.9×	1.2k 0.5×	2.3k 1.4×	1.3k 0.9×	2.4k 2.1×	148	8.3k
Alex Avdeef United States	55	2.5k 0.7×	2.1k 1.0×	712 0.4×	1.6k 1.1×	1.8k 1.5×	139	9.9k
Gabriele Cruciani Italy	55	5.0k 1.4×	1.1k 0.5×	975 0.6×	3.6k 2.4×	2.4k 2.1×	223	10.5k

Countries citing papers authored by Li Di

Since Specialization

Citations

This map shows the geographic impact of Li Di's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li Di with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li Di more than expected).

Fields of papers citing papers by Li Di

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Li Di. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li Di. The network helps show where Li Di may publish in the future.

Co-authorship network of co-authors of Li Di

This figure shows the co-authorship network connecting the top 25 collaborators of Li Di. A scholar is included among the top collaborators of Li Di based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Li Di. Li Di is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Yutong, Shangkun Li, Lidong Lin, et al.. (2025). In vitro simulated digestion and fermentation characteristics of polyphenol–polysaccharide complex from Hizikia fusiforme and its effects on the human gut microbiota. International Journal of Biological Macromolecules. 302. 140619–140619. 4 indexed citations

Liu, Xi, Long‐Yuan Li, Lei Bai, et al.. (2025). GrpEL1 overexpression mitigates hippocampal neuron damage via mitochondrial unfolded protein response after experimental status epilepticus. Neurobiology of Disease. 206. 106838–106838.

Li, Shangkun, Yutong Li, Fangjie Cao, et al.. (2025). The impact of Hizikia fusiforme polyphenol–polysaccharide complex on oxidative stress, inflammation and gut dysbiosis of D-galactose-inducde aging mice. International Journal of Biological Macromolecules. 330(Pt 1). 147975–147975.

Wen, Qi, Haoran Liu, Yuting Jiang, et al.. (2025). Short-term and long-term prognoses in AChR-Ab positive very-late-onset myasthenia gravis patients. Therapeutic Advances in Neurological Disorders. 18. 4233590881–4233590881. 4 indexed citations

Zhu, Wenjia, Yuping Chen, Cong Tian, et al.. (2025). Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study. Journal of Neurology. 272(9). 622–622.

Wen, Xinmei, Xin‐Ming Shen, Li Di, et al.. (2024). A rare complex structural variant of novel intragenic inversion combined with reciprocal translocation t(X;1)(p21.2;p13.3) in Duchenne muscular dystrophy. Neuromuscular Disorders. 39. 24–29. 1 indexed citations

Xie, Weiwei, Li Di, Peijun Li, et al.. (2024). L ‐ascorbyl‐2‐phosphate alleviates white matter injury caused by chronic hypoxia through the PRMT5 / P53 / NF‐κB pathway. Journal of Neurochemistry. 168(2). 142–160. 2 indexed citations

Li, Yutong, Shangkun Li, Li Di, et al.. (2024). In Vivo Tissue Distribution and Pharmacokinetics of FITC-Labelled Hizikia fusiforme Polyphenol–Polysaccharide Complex in Mice. Foods. 13(18). 3019–3019. 4 indexed citations

Liu, Jianhua, Anthony Carlo, Woodrow Burchett, et al.. (2024). Novel Multiplexed High Throughput Screening of Selective Inhibitors for Drug-Metabolizing Enzymes Using Human Hepatocytes. The AAPS Journal. 26(3). 36–36. 3 indexed citations

10.

Chen, Jie, et al.. (2024). Characterization of CYP3A5 Selective Inhibitors for Reaction Phenotyping of Drug Candidates. The AAPS Journal. 26(2). 26–26. 1 indexed citations

11.

Weng, Yan, Kari R. Fonseca, Yi‐An Bi, et al.. (2022). Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, a First-In-Class Ketohexokinase Inhibitor for Metabolic Disorders and Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition. 50(9). 1312–1321. 6 indexed citations

12.

Feng, Bo, Angela C. Doran, Li Di, et al.. (2018). Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models. Journal of Pharmaceutical Sciences. 107(8). 2225–2235. 27 indexed citations

13.

Riccardi, Keith, Jian Lin, Mark Niosi, et al.. (2017). Novel Method to Predict In Vivo Liver-to-Plasma Kpuu for OATP Substrates Using Suspension Hepatocytes. Drug Metabolism and Disposition. 45(5). 576–580. 42 indexed citations

14.

Gao, Yumei, Li Di, Hong Cheng, & Yipu Chen. (2014). Derivation and validation of a risk score for contrast-induced nephropathy after cardiac catheterization in Chinese patients. Clinical and Experimental Nephrology. 18(6). 892–898. 39 indexed citations

15.

Di, Li. (2013). The effects of CLP-19 on inflammatory factors regulation in RAW264.7 cells. Immunological Journal. 1 indexed citations

16.

Yates, Phillip D., Heather Eng, Li Di, & R. Scott Obach. (2012). Statistical Methods for Analysis of Time-Dependent Inhibition of Cytochrome P450 Enzymes. Drug Metabolism and Disposition. 40(12). 2289–2296. 24 indexed citations

17.

Di, Li, John P. Umland, George Chang, et al.. (2011). Species Independence in Brain Tissue Binding Using Brain Homogenates. Drug Metabolism and Disposition. 39(7). 1270–1277. 114 indexed citations

18.

Zhang, Jing, et al.. (2011). Antioxidant Function of Flavonoids from Songaria cynomorium Herb. Medicinal plant. 2(12). 14–16. 1 indexed citations

19.

Di, Li, Edward H. Kerns, Susan Q. Li, & Susan Petusky. (2006). High throughput microsomal stability assay for insoluble compounds. International Journal of Pharmaceutics. 317(1). 54–60. 49 indexed citations

20.

Kerns, Edward H., Li Di, Jonathan A. Gross, et al.. (2005). Integrity Profiling of High Throughput Screening Hits Using LC-MS and Related Techniques. Combinatorial Chemistry & High Throughput Screening. 8(6). 459–466. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact